Blocking SLAMF7 thickens the gut's mucus barrier and shields mice from colitis
Mice lacking the immune receptor SLAMF7 had more goblet cells, a thicker mucus layer, more Akkermansia, and milder DSS-induced colitis.
Resumo
Inflammatory bowel disease (IBD) often resists current drugs, so researchers are looking for new drivers of gut inflammation. This mouse study examined SLAMF7, an immune receptor found on macrophages. SLAMF7 levels were higher in human colitis tissue and in inflamed mouse colon. Mice lacking SLAMF7 were protected from chemically induced colitis. They lost less weight, kept longer colons, had milder tissue damage, showed stronger tight-junction proteins, and had lower mortality. According to the authors, SLAMF7 loss shifted macrophages toward a C1q-producing, M2-like state through STAT6-MafB signaling. This increased goblet cells and mucus and favored the mucus-dwelling bacterium Akkermansia muciniphila. Activating SLAMF7 had the opposite effect, while silencing it with siRNA eased colitis. SLAMF7 is therefore a candidate target for restoring gut barrier health, but the evidence so far comes from mice.
Resumo Detalhado
Why it matters: IBD, which includes Crohn's disease and ulcerative colitis, is a chronic, relapsing condition that is still hard to treat. Roughly 20–40% of patients do not respond to anti-TNF-α induction therapy, and nearly half of initial responders later lose response. A fuller understanding of how immune cells, the mucus barrier, and gut microbes interact could point to new, more personalized targets. Macrophages are increasingly recognized as regulators of goblet cells and mucus maintenance, not just of inflammation.
What was studied: The team asked whether SLAMF7, a SLAM-family receptor expressed mainly on macrophages and NK cells, shapes gut homeostasis. SLAMF7 had previously been described as a brake on inflammation in sepsis. The researchers first checked public human gene-expression data (ten healthy donors versus ten colitis patients) and a mouse model of dextran sulfate sodium (DSS) colitis. They then compared wild-type C57BL/6J mice with Slamf7-knockout mice, and later used SLAMF7 activation and siRNA knockdown to test the effect in the other direction. Detailed methods were in the supplement, which was not available for this summary.
Key results: SLAMF7 expression was significantly higher in colon tissue from colitis patients than from healthy donors, and it rose in mouse colon during DSS inflammation. Unexpectedly, SLAMF7 loss was protective. Knockout mice showed less weight loss, longer colons, lower disease activity index scores, less mortality, milder histopathology with intact crypts, and higher ZO-1 and claudin-4 tight-junction proteins than wild-type mice. According to the abstract, SLAMF7 deficiency also changed the gut microbiota, notably expanding the mucus-associated bacterium Akkermansia muciniphila. It increased goblet cell generation and mucus thickness by increasing M2-like C1q+ macrophages. Mechanistically, SLAMF7 depletion in macrophages upregulated C1q through the STAT6-MafB pathway and biased cells toward an M2 phenotype when exposed to damage-associated molecular patterns (DAMPs). SLAMF7 activation shifted macrophage polarization, reduced mucus secretion, and worsened inflammation, while SLAMF7 siRNA knockdown eased DSS colitis.
Implications: The work suggests SLAMF7 acts as a negative regulator of gut barrier health. Inhibiting it could support macrophage-driven goblet cell and mucus production and favor beneficial commensals. This frames SLAMF7 as a possible therapeutic target or biomarker in IBD.
Caveats: The evidence is preclinical, based on mice and a small public human dataset. The abstract's wording ("partly," "to some extent") indicates that macrophage polarization and mucus effects explain only part of the protection. Whether SLAMF7 blockade is safe or effective in people is unknown. The text supplied here ended partway through the first results section, so later experiments are summarized from the abstract.
Principais Descobertas
- SLAMF7 expression was significantly higher in colon tissue of colitis patients than in healthy donors, and rose in DSS-inflamed mouse colon.
- Slamf7-knockout mice had less weight loss, longer colons, lower disease scores, milder histopathology, and lower mortality after DSS than wild-type mice.
- SLAMF7 deficiency raised ZO-1 and claudin-4 tight-junction proteins and expanded mucus-associated Akkermansia muciniphila.
- Loss of SLAMF7 upregulated C1q via STAT6-MafB, promoting M2-like macrophages and increasing goblet cells and mucus thickness.
- SLAMF7 activation reduced mucus and worsened colitis, whereas SLAMF7 siRNA knockdown partly alleviated DSS-induced inflammation.
Metodologia
Preclinical study using Slamf7-knockout and wild-type C57BL/6J mice (8–14 weeks old, SPF housing) in a DSS-induced acute colitis model, plus public human colon gene-expression data (10 healthy, 10 colitis). Readouts included weight, colon length, disease activity index, histology, tight-junction proteins, microbiota composition, and macrophage/goblet cell phenotypes. SLAMF7 activation and siRNA knockdown were used as complementary tests.
Limitações do Estudo
All causal evidence comes from mouse models, mainly acute DSS colitis, and the human data are a small public dataset of 20 donors. The authors note that macrophage polarization explains the effects only partly, and the knockout is global rather than cell-specific. The supplied text was truncated and the supplementary methods were unavailable, so details such as sample sizes, sex, and statistics could not be verified.
Gostou deste resumo?
Receba as pesquisas de longevidade mais recentes na sua caixa de entrada toda semana.
Digite seu e-mail para assinar: